Impact of Human Papillomavirus Status on Hypercoagulable Events in Oropharyngeal Squamous Cell Carcinoma
DOI:
https://doi.org/10.52845/JORR/2023/4.3.5Abstract
Objective: To determine whether HPV status impacts the incidence of hypercoagulable events in patients with OSCC.
Methods: Medical records for n=143 patients with a clinical diagnosis of OSCC and documented HPV status were abstracted from a head and neck cancer data base at Cooper University Hospital in Camden, NJ. Data regarding demographics, malignancy staging and treatment, clinical variables, and hypercoagulable events were recorded from the database and electronic medical record. Primary outcomes included the occurrence of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and/or transient ischemic attack (TIA) either before, during, or after treatment of OSCC. Logistic regression modeling and fisher exact testing were utilized to compare rates of hypercoagulable events in HPV positive and HPV negative OSCC patients.
Results: Logistic regression modeling revealed odds ratios (OR) with no statistically significant relationship between HPV positive status and rates of DVT [OR: 0.9804, 95% CI (0.225, 4.278)], PE [OR: 0.584, 95% CI (0.36, 9.40)], stroke [OR: 0.363, 95% CI (0.123, 1.020)], and TIA [OR: 0.278, 95% CI (0.049, 1.575)]. Fisher exact testing revealed similar results for DVT (P=1.0), PE (P=1.0), stroke (P=0.062), and TIA (P=0.195).
Conclusion: Overall, no significant differences were identified in the rates of hypercoagulable events in HPV positive compared to HPV negative cohorts, suggesting the virus has no impact on thrombosis risk in OSCC patients.
References
Mehanna, H. et al.Prevalence of human papilloma-virus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region. HeadNeck35, 747–755 (2013).
Haen, P. et al.Oral Squamous Cell Carcinoma Is Associated with a Low Thrombosis Risk Due to
Storage Pool Deficiency in Platelets.Biomedicines 9, (2021).
Christensen, A. et al.Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer. BMC Cancer17, 572 (2017).
Chang, M.-C. et al.Signaling pathways for induction of platelet aggregation by SAS tongue
cancer cells - a mechanism of hematogenous metastasis. J. Oral Pathol. Med.38, 434–440 (2008).
Ren, J. G. et al.Elevated Level of Circulating Platelet-derived Microparticles in Oral Cancer. J.
Dent. Res.95, 87–93 (2016).
Parks, R. R., Yan, S.-D. & Huang, C.-C. Tumor Necrosis Factor-Alpha Production in Human Head and Neck Squamous Cell Carcinoma.Laryngoscope 104, 860???864 (1994).
Wakasaki, T. et al.Massive internal jugular vein tumor thrombus derived from squamous cell
carcinoma of the head and neck: two case reports. Oral Maxillofac. Surg.21, 69–74 (2017).
Aoyama, K. et al.Trousseau syndrome in a patient with advanced oral squamous cell carcinoma: a case report. J. Med. Case Rep.13, 26 (2019).
Rinaldi, I., Hardjolukito, E., Kurniawan, A. & Hermani, B. MEDICAL ILLUSTRATION DVT in Tonsil Sarcoma.
Haen, P. et al.Thrombosis Risk Associated with Head and Neck Cancer: A Review. Int. J. Mol.
Sci.20, (2019).
O’Sullivan, B. et al.Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet.Oncol.17, 440–451 (2016).
Amin, M. B., Edge, S. B. & American Joint Committee on Cancer. AJCC cancer staging manual.
Lyman, G. H. et al.Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 31, 2189–204 (2013).
Paneesha, S. et al.Frequency, demographics and risk (according to tumour type or site) of
cancer-associated thrombosis among patients seen at outpatient DVT clinics. Thromb. Haemost.103, 338–343 (2010).
Bahl, V. et al. Chemoprophylaxis for Venous Thromboembolism in Otolaryngology .JAMA Otolaryngol. Neck Surg.140, 999 (2014).
Cramer, J. D., Shuman, A. G. & Brenner, M. J. Antithrombotic Therapy for Venous Thromboemb -olism and Prevention of Thrombosis in Otolaryngology-Head and Neck
Surgery: State of the Art Review. Otolaryngol. Head. Neck Surg.158, 627–636 (2018).
Shuman, A. G. et al.Stratifying the risk of venous thromboembolism in otolaryngology.
Otolaryngol. Head. Neck Surg.146, 719–24(2012).
Lakhani, R., Narwani, V., Bromby, A. & Hilger, A. W. Venous thromboembolism in ENT surgery: a review of the literature and completed audit cycle of adherence to national guidance. Eur. Arch. Oto-Rhino-Laryngology 270, 2559–2564 (2013).
Clayburgh, D. et al. Prospective Study of Venous Thromboembolism in Patients With
Head and Neck Cancer After Surgery. JAMA Otolaryngol. Neck Surg. 139, 161 (2013).
